Ovid Therapeutics
New York, NY · Founded 2014 · CIK 0001636651 · Biotech · Public
Small molecule therapeutics for rare epilepsy disorders, including soticlestat and OV329
ovidtx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $106M
- 3 Form D · Jan 2017
- 117 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 10 granted · 30 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201520162017
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $5,060,000 | |
| Private capital raised | Form D · SEC | $74,999,893 | |
| Private capital raised | Form D · SEC | $25,861,228 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2820 | Passage Bio | — | $110M |
| 2821 | Acadia Pharmaceuticals | — | $107M |
| 2822 | Neurogene Inc. | — | $106M |
| 2823 | Ovid Therapeutics | — | $106M |
| 2824 | LEAP THERAPEUTICS, INC. | — | $105M |
| 2825 | CENTRILLION BIOSCIENCES, INC. | — | — |
| 2826 | Adaptimmune | — | $104M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Karen BernsteinDirector
- Matthew DuringDirector · Executive Officer
- Mark FeldbergDirector
- Bart FriedmanDirector
- Jeremy LevinDirector · Executive Officer
- Amit RakhitExecutive Officer
- Yaron WerberExecutive Officer
- Douglas WilliamsDirector
Patents
- Fused Amino Pyrimidine Compounds For Treatment Of Overweight And Obesityapplication
- FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF 22q11.2 DELETION/DUPLICATION SYNDROMESapplication
- Fused Amino Pyrimidine Compounds For Treatment Of Autism Spectrum Disorder, Obsessive Compulsive Disorder And Ticsapplication
- Fused Amino Pyrimidine Compounds For Treatment Of Addiction And Insomniaapplication
- Use Of (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC Acid In The Treatment Of Painapplication
- Fused Amino Pyrimidine Compounds For Treatment Of Tinnitus, Acute Sensorineural Hearing Loss, Age-related Hearing Loss, And Meniere's Diseaseapplication
- Fused Amino Pyrimidine Compounds For Treatment Of Psychosis And Psychotic Disordersapplication
- Fused Amino Pyrimidine Compounds For Treatment Of Neurodegenerative Disordersapplication
- Methods Of Treating Developmental Disorders With Gaboxadolgranted
- Fused Amino Pyrimidine Compounds And Pridopidine For Treatment Of Huntington’s Diseaseapplication
- Fused Amino Pyrimidine Compounds For Treatment Of Seizure Disordersapplication
- Fused Amino Pyrimidine Compounds For Treatment Of Neuropathic And Neuro-inflammatory Painapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.